DDW speaks to Yasuo Nakamura, Senior Executive Officer at Pharmaceuticals R&D, Asahi Kasei Pharma Corporation about the challenges of treating chemotherapy-induced peripheral neuropathy (CIPN) and the company’s current pipeline targeting the condition. DDW: What makes chemotherapy-induced peripheral neuropathy (CIPN) such a persistent challenge in colorectal cancer care, and why has prevention proven so elusive? YN: […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!